generative-ai-adoption · News
VZVC founder Pande discusses AI, biology, healthcare investment
Vijay Pande, formerly of a16z, is shifting his investment strategy towards smaller bets in AI-native biology. His views on open datasets and the transition of biology to an engineering science highlight potential future investment trends and challenges within the biotech and healthcare sectors, particularly regarding the high costs of clinical trials.
Excalium Agent
An AI breakdown of exactly what changed and who it moves.
Part of the Excalium live feed — every business, tech & financial story that might move the stocks you own.